Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as monoclonal antibody
TEV-48125- 1 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| TEV-48125 - 1 | EXPERIMENTAL | Dose Regimen 1 |
| TEV-48125 - 2 | EXPERIMENTAL | Dose Regimen 2 |
| TEV-48125 - 3 | EXPERIMENTAL | Dose Regimen 3 |
| Placebo | PLACEBO_COMPARATOR | Matching Placebo |
| Name | Type | Description |
|---|---|---|
| TEV-48125 - 1 | DRUG | Subcutaneous administration Dose Regimen 1 |
| TEV-48125 - 2 | DRUG | Subcutaneous administration Dose Regimen 2 |
| TEV-48125 - 3 | DRUG | Subcutaneous administration Dose Regimen 3 |
| Placebo | DRUG | Matching Placebo |
Inclusion Criteria: * The subject is a man or woman, 18 to 55 years of age, inclusive * The subject has a body mass index (BMI) ranging from 17.5 to 28.0 kg/m2, inclusive * The subjects must be in a good health at screening and check-in Additional inclusion criteria for Japanese subjects: * Subje...
TEV-48125- 1 is an investigational small molecule developed by Teva Pharmaceutical Industries Limited. It has been studied in a Phase 1 clinical trial in healthy adult volunteers, focused on pharmacokinetics, safety, and tolerability after a single subcutaneous administration. Its specific therapeutic indication has not been disclosed.
TEV-48125- 1 is being developed by Teva Pharmaceutical Industries Limited, which trades under the ticker TEVA. Teva sponsored the Phase 1 study of the compound in healthy subjects.
TEV-48125- 1 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The compound remains investigational and has not been approved by the FDA.
TEV-48125- 1 has been evaluated in a single completed Phase 1 trial, NCT02673567. The study assessed pharmacokinetics, safety, and tolerability of a single subcutaneous dose in Japanese and Caucasian healthy subjects. It enrolled 64 participants, was randomized, double blind, and placebo controlled, and was conducted in the United States.
Yes, TEV-48125- 1 and TEV-48125 - 1 refer to the same investigational compound from Teva Pharmaceutical Industries Limited. The two spellings differ only by spacing in the designation.